Bayer announced an agreement to acquire Noria Therapeutics Inc. and PSMA Therapeutics Inc. in an effort to expand the global biopharmaceutical company’s portfolio of targeted alpha radionuclide therapies for prostate cancer.
Clovis Oncology Inc. entered into a global licensing and collaboration agreement with 3B Pharmaceuticals GmbH, a private German biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for oncology indications with a high unmet medical need.
